octreotide: profile and news

Researchers' findings from the United States and Germany advance ...  May 11, 2006
Study 1: Octreotide LAR given at 40 or 60 mg resulted in statistically significant weight loss in obese adults with insulin hypersecretion. ... - Therapeutics Daily (subscription) (press release),

Ambrilia Announces First Quarter 2006 Results and Provides Update ...  May 10, 2006
Effectively implemented a sterile manufacturing chain and produced batches of Octreotide in compliance with clinical use regulations and which showed a ... - Market Wire (press release)

Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 ...  May 11, 2006
Ambrilia's product portfolio includes mid to early-stage products (PPL-100, PCK3145, TVT-Dox, SPC3) and two specialty generics (Octreotide and Goserelin), the ... - Genetic Engineering News,

Expression of Protein Kinase CK2 in Astroglial Cells of Normal and ...  May 2, 2006
Here we describe retinal CK2 expression and combined effects of CK2 inhibitors with the somatostatin analog octreotide in a mouse model of oxygen-induced ... - Am J Pathology (subscription)

Pasireotide (SOM230) Shows Promise for Treating Acromegaly ...  May 2, 2006
..."Early data from phase 2 studies in metastatic carcinoid tumors resistant/refractory to Sandostatin LAR [octreotide injection], acromegaly, and Cushing's ... - DG News

Valera Pharmaceuticals Reports First Quarter 2006 Financial ...  Apr 27, 2006
VP003, a six month implant delivering octreotide for the treatment of acromegaly, will enter Phase III clinical trials, rather than Phase IIb trials, later ... - Business Wire (press release),

Ambrilia Announces Board Appointments: Joseph J. Krivulka and ...  May 9, 2006
...promising anti-HIV treatments (PPL-100, SPC3), a tumor vasculature targeting technology (TVT-Dox) and two specialty generics (Octreotide, Goserelin), the first ... - Market Wire (press release)